Drug-drug  ||| S:0 E:10 ||| JJ
interactions  ||| S:10 E:23 ||| NNS
with  ||| S:23 E:28 ||| IN
raltegravir  ||| S:28 E:40 ||| VBG
To  ||| S:40 E:43 ||| TO
review  ||| S:43 E:50 ||| VB
all  ||| S:50 E:54 ||| DT
currently  ||| S:54 E:64 ||| RB
published  ||| S:64 E:74 ||| VBN
drug-drug  ||| S:74 E:84 ||| JJ
interaction  ||| S:84 E:96 ||| JJ
studies  ||| S:96 E:104 ||| NNS
with  ||| S:104 E:109 ||| IN
the  ||| S:109 E:113 ||| DT
HIV-integrase  ||| S:113 E:127 ||| JJ
inhibitor  ||| S:127 E:137 ||| JJ
raltegravir ||| S:137 E:148 ||| NN
.  ||| S:148 E:150 ||| .
A  ||| S:150 E:152 ||| DT
PubMed  ||| S:152 E:159 ||| JJ
search  ||| S:159 E:166 ||| NN
was  ||| S:166 E:170 ||| VBD
conducted  ||| S:170 E:180 ||| VBN
for  ||| S:180 E:184 ||| IN
all  ||| S:184 E:188 ||| DT
published  ||| S:188 E:198 ||| JJ
reports  ||| S:198 E:206 ||| NNS
up  ||| S:206 E:209 ||| RB
to  ||| S:209 E:212 ||| TO
August  ||| S:212 E:219 ||| NNP
1 ||| S:219 E:220 ||| CD
,  ||| S:220 E:222 ||| ,
2009  ||| S:222 E:227 ||| CD
as  ||| S:227 E:230 ||| IN
well  ||| S:230 E:235 ||| RB
as  ||| S:235 E:238 ||| IN
a  ||| S:238 E:240 ||| DT
review  ||| S:240 E:247 ||| NN
of  ||| S:247 E:250 ||| IN
updated  ||| S:250 E:258 ||| JJ
European  ||| S:258 E:267 ||| JJ
and  ||| S:267 E:271 ||| CC
US  ||| S:271 E:274 ||| NNP
Prescriber ||| S:274 E:284 ||| NNP
's  ||| S:284 E:287 ||| POS
Information  ||| S:287 E:299 ||| NNP
( ||| S:299 E:300 ||| -LRB-
EMEA  ||| S:300 E:305 ||| NNP
and  ||| S:305 E:309 ||| CC
FDA ||| S:309 E:312 ||| NNP
)  ||| S:312 E:314 ||| -RRB-
and  ||| S:314 E:318 ||| CC
abstracts  ||| S:318 E:328 ||| NNS
from  ||| S:328 E:333 ||| IN
recent  ||| S:333 E:340 ||| JJ
international  ||| S:340 E:354 ||| JJ
scientific  ||| S:354 E:365 ||| JJ
meetings ||| S:365 E:373 ||| NNS
.  ||| S:373 E:375 ||| .
A  ||| S:375 E:377 ||| DT
total  ||| S:377 E:383 ||| NN
of  ||| S:383 E:386 ||| IN
14  ||| S:386 E:389 ||| CD
drug-drug  ||| S:389 E:399 ||| JJ
interaction  ||| S:399 E:411 ||| JJ
studies  ||| S:411 E:419 ||| NNS
were  ||| S:419 E:424 ||| VBD
found ||| S:424 E:429 ||| VBN
.  ||| S:429 E:431 ||| .
Due  ||| S:431 E:435 ||| JJ
to  ||| S:435 E:438 ||| TO
the  ||| S:438 E:442 ||| DT
relatively  ||| S:442 E:453 ||| RB
broad  ||| S:453 E:459 ||| JJ
therapeutic  ||| S:459 E:471 ||| JJ
range  ||| S:471 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
raltegravir  ||| S:480 E:492 ||| VBG
almost  ||| S:492 E:499 ||| RB
all  ||| S:499 E:503 ||| DT
co-administered  ||| S:503 E:519 ||| JJ
agents  ||| S:519 E:526 ||| NNS
can  ||| S:526 E:530 ||| MD
safely  ||| S:530 E:537 ||| RB
be  ||| S:537 E:540 ||| VB
combined  ||| S:540 E:549 ||| VBN
with  ||| S:549 E:554 ||| IN
raltegravir ||| S:554 E:565 ||| NN
,  ||| S:565 E:567 ||| ,
with  ||| S:567 E:572 ||| IN
the  ||| S:572 E:576 ||| DT
exception  ||| S:576 E:586 ||| NN
of  ||| S:586 E:589 ||| IN
rifampin  ||| S:589 E:598 ||| NN
in  ||| S:598 E:601 ||| IN
which  ||| S:601 E:607 ||| WDT
a  ||| S:607 E:609 ||| DT
doubling  ||| S:609 E:618 ||| NN
of  ||| S:618 E:621 ||| IN
the  ||| S:621 E:625 ||| DT
raltegravir  ||| S:625 E:637 ||| JJ
dose  ||| S:637 E:642 ||| NN
to  ||| S:642 E:645 ||| TO
800  ||| S:645 E:649 ||| CD
mg  ||| S:649 E:652 ||| JJ
BD  ||| S:652 E:655 ||| NNP
is  ||| S:655 E:658 ||| VBZ
currently  ||| S:658 E:668 ||| RB
recommended ||| S:668 E:679 ||| VBN
.  ||| S:679 E:681 ||| .
Raltegravir  ||| S:681 E:693 ||| NNP
is  ||| S:693 E:696 ||| VBZ
not  ||| S:696 E:700 ||| RB
without  ||| S:700 E:708 ||| IN
drug-drug  ||| S:708 E:718 ||| JJ
interactions  ||| S:718 E:731 ||| NNS
but  ||| S:731 E:735 ||| CC
due  ||| S:735 E:739 ||| JJ
to  ||| S:739 E:742 ||| TO
the  ||| S:742 E:746 ||| DT
lack  ||| S:746 E:751 ||| NN
of  ||| S:751 E:754 ||| IN
an  ||| S:754 E:757 ||| DT
effect  ||| S:757 E:764 ||| NN
on  ||| S:764 E:767 ||| IN
CYP450  ||| S:767 E:774 ||| NNP
or  ||| S:774 E:777 ||| CC
UGT  ||| S:777 E:781 ||| NNP
by  ||| S:781 E:784 ||| IN
raltegravir  ||| S:784 E:796 ||| NN
and  ||| S:796 E:800 ||| CC
the  ||| S:800 E:804 ||| DT
broad  ||| S:804 E:810 ||| JJ
therapeutic  ||| S:810 E:822 ||| JJ
range  ||| S:822 E:828 ||| NN
of  ||| S:828 E:831 ||| IN
raltegravir  ||| S:831 E:843 ||| VBG
itself ||| S:843 E:849 ||| PRP
,  ||| S:849 E:851 ||| ,
this  ||| S:851 E:856 ||| DT
agent  ||| S:856 E:862 ||| NN
can  ||| S:862 E:866 ||| MD
safely  ||| S:866 E:873 ||| RB
combined  ||| S:873 E:882 ||| VBN
with  ||| S:882 E:887 ||| IN
almost  ||| S:887 E:894 ||| RB
all  ||| S:894 E:898 ||| DT
tested  ||| S:898 E:905 ||| JJ
agents ||| S:905 E:911 ||| NNS
.  ||| S:911 E:913 ||| .
